NO20023997L - 2-okso-1-pyrrolidinderivater, fremgangsmåter for deres fremstilling, og deres anvendelse - Google Patents

2-okso-1-pyrrolidinderivater, fremgangsmåter for deres fremstilling, og deres anvendelse

Info

Publication number
NO20023997L
NO20023997L NO20023997A NO20023997A NO20023997L NO 20023997 L NO20023997 L NO 20023997L NO 20023997 A NO20023997 A NO 20023997A NO 20023997 A NO20023997 A NO 20023997A NO 20023997 L NO20023997 L NO 20023997L
Authority
NO
Norway
Prior art keywords
sup
oxo
pyrrolidine derivatives
processes
preparation
Prior art date
Application number
NO20023997A
Other languages
English (en)
Other versions
NO20023997D0 (no
NO324485B1 (no
Inventor
Edmond Differding
Benoit Kenda
Benedicte Lallemand
Alain Matagne
Philippe Michel
Patrick Pasau
Patrice Talaga
Original Assignee
Ucb Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9886259&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20023997(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ucb Sa filed Critical Ucb Sa
Publication of NO20023997D0 publication Critical patent/NO20023997D0/no
Publication of NO20023997L publication Critical patent/NO20023997L/no
Publication of NO324485B1 publication Critical patent/NO324485B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C237/12—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C07D207/263—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms
    • C07D207/27—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms with substituted hydrocarbon radicals directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C07D207/273—2-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C07D207/273—2-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
    • C07D207/277—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/44—Radicals substituted by doubly-bound oxygen, sulfur, or nitrogen atoms, or by two such atoms singly-bound to the same carbon atom
    • C07D213/46—Oxygen atoms
    • C07D213/50—Ketonic radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/26—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D307/30—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/32—Oxygen atoms
    • C07D307/33—Oxygen atoms in position 2, the oxygen atom being in its keto or unsubstituted enol form
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
    • C07D333/20—Radicals substituted by singly bound hetero atoms other than halogen by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Addiction (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Otolaryngology (AREA)
  • Immunology (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Hydrogenated Pyridines (AREA)
NO20023997A 2000-02-23 2002-08-22 2-okso-1-pyrrolidinderivater, farmasøytisk preparat og deres anvendelse for fremstilling av et medikament NO324485B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0004297.8A GB0004297D0 (en) 2000-02-23 2000-02-23 2-oxo-1 pyrrolidine derivatives process for preparing them and their uses
PCT/EP2001/001992 WO2001062726A2 (en) 2000-02-23 2001-02-21 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses

Publications (3)

Publication Number Publication Date
NO20023997D0 NO20023997D0 (no) 2002-08-22
NO20023997L true NO20023997L (no) 2002-10-22
NO324485B1 NO324485B1 (no) 2007-10-29

Family

ID=9886259

Family Applications (6)

Application Number Title Priority Date Filing Date
NO20023995A NO324051B1 (no) 2000-02-23 2002-08-22 2-okso-1-pyrrolidinderivater, fremgangsmate for fremstilling av disse og anvendelse av dem
NO20023997A NO324485B1 (no) 2000-02-23 2002-08-22 2-okso-1-pyrrolidinderivater, farmasøytisk preparat og deres anvendelse for fremstilling av et medikament
NO20053644A NO20053644L (no) 2000-02-23 2005-07-27 (2S)-2-[(4S)-4-(2,2-difluorvinyl)-2-oksopyrrolidinyl ]butanamid og farmasoytisk preparat
NO20053645A NO20053645L (no) 2000-02-23 2005-07-27 (4R)- og (4S)-diastereoisomerer av (2S)-2-[ 2-oksy-4-propylpyrrolidinyl]butanamid og farmasoytisk preparat inneholdende disse
NO2016005C NO2016005I1 (no) 2000-02-23 2016-03-08 2-okso-1-pyrrolidinderivater, farmasøytisk preparat og deres anvendelse for fremstilling av et medikament
NO2023025C NO2023025I1 (no) 2000-02-23 2023-06-20 Brivaracetam - forlengelse

Family Applications Before (1)

Application Number Title Priority Date Filing Date
NO20023995A NO324051B1 (no) 2000-02-23 2002-08-22 2-okso-1-pyrrolidinderivater, fremgangsmate for fremstilling av disse og anvendelse av dem

Family Applications After (4)

Application Number Title Priority Date Filing Date
NO20053644A NO20053644L (no) 2000-02-23 2005-07-27 (2S)-2-[(4S)-4-(2,2-difluorvinyl)-2-oksopyrrolidinyl ]butanamid og farmasoytisk preparat
NO20053645A NO20053645L (no) 2000-02-23 2005-07-27 (4R)- og (4S)-diastereoisomerer av (2S)-2-[ 2-oksy-4-propylpyrrolidinyl]butanamid og farmasoytisk preparat inneholdende disse
NO2016005C NO2016005I1 (no) 2000-02-23 2016-03-08 2-okso-1-pyrrolidinderivater, farmasøytisk preparat og deres anvendelse for fremstilling av et medikament
NO2023025C NO2023025I1 (no) 2000-02-23 2023-06-20 Brivaracetam - forlengelse

Country Status (43)

Country Link
US (12) US6713635B2 (no)
EP (8) EP1577296A1 (no)
JP (5) JP4121744B2 (no)
KR (4) KR100816185B1 (no)
CN (5) CN1303066C (no)
AT (5) ATE282592T1 (no)
AU (5) AU5214401A (no)
BE (1) BE2016C012I2 (no)
BG (4) BG65923B1 (no)
BR (2) BRPI0108664B8 (no)
CA (2) CA2401033C (no)
CO (2) CO5280059A1 (no)
CU (2) CU23293B7 (no)
CY (3) CY1105517T1 (no)
CZ (3) CZ304702B6 (no)
DE (5) DE60113514T2 (no)
DK (3) DK1447399T3 (no)
EG (1) EG24375A (no)
ES (5) ES2355140T3 (no)
FR (1) FR16C1001I2 (no)
GB (1) GB0004297D0 (no)
HK (2) HK1052516B (no)
HU (4) HU229514B1 (no)
IL (5) IL150757A0 (no)
IS (8) IS2119B (no)
LT (1) LTC1265862I2 (no)
LU (1) LU92993I2 (no)
ME (1) ME00595B (no)
MX (2) MXPA02008056A (no)
MY (4) MY138966A (no)
NL (1) NL300815I2 (no)
NO (6) NO324051B1 (no)
NZ (1) NZ520448A (no)
PL (3) PL212197B1 (no)
PT (2) PT1452524E (no)
RO (2) RO121597B1 (no)
RS (2) RS50455B (no)
RU (5) RU2355680C2 (no)
SA (2) SA01220027B1 (no)
SI (1) SI1265862T1 (no)
TW (2) TW200626545A (no)
WO (2) WO2001062726A2 (no)
ZA (2) ZA200205671B (no)

Families Citing this family (157)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7365093B2 (en) * 1994-08-19 2008-04-29 Abbott Laboratories Endothelin antagonists
GB0004297D0 (en) * 2000-02-23 2000-04-12 Ucb Sa 2-oxo-1 pyrrolidine derivatives process for preparing them and their uses
US6686477B2 (en) 2000-09-29 2004-02-03 Eastman Chemical Company Highly enantiomerically pure lactam-substituted propanoic acid derivatives and methods of making and using same
JP2004523557A (ja) * 2001-02-23 2004-08-05 ジョンズ・ホプキンス・ユニバーシティ チック、振せん、および関連疾患の治療
ATE410412T1 (de) 2001-08-10 2008-10-15 Ucb Pharma Sa Oxopyrrolidin verbindungen, verfahren zur herstellung dieser verbindungen und deren verwendung zur herstellung von levetiracetam und analogen
CA2461961A1 (en) * 2001-10-08 2003-04-17 Ucb, S.A. Use of 2-oxo-1-pyrrolidine derivatives for the treatment of dyskinesia and movement disorders
CN1604776A (zh) 2001-10-16 2005-04-06 记忆药物公司 作为用于治疗神经病综合症的pde－4抑制剂的4－(4－烷氧基－3－羟基苯基)－2－吡咯烷酮衍生物
AU2003242538A1 (en) * 2002-05-14 2003-11-11 Ucb, S.A. Use of 2-oxo-1-pyrrolidone derivatives for the preparation of a drug
AU2004204338A1 (en) * 2003-01-13 2004-07-29 Ucb Hydrogenation catalysts
EP1517893A2 (en) * 2003-02-03 2005-03-30 Teva Pharmaceutical Industries Limited Process for producing levetiracetam
ES2214147B1 (es) 2003-02-28 2005-10-01 Farma-Lepori S.A. Procedimiento de obtencion de un agente antiepileptico.
TR200503397T1 (tr) * 2003-03-18 2007-03-21 Hetero Drugs Limited Levetirasetam'ın yeni kristal formları.
RU2232578C1 (ru) * 2003-04-10 2004-07-20 Ахапкина Валентина Ивановна Вещество, обладающее антидепрессивной активностью
SG169900A1 (en) 2003-04-16 2011-04-29 Memory Pharm Corp 4 - (3,4 - disubstituted phenyl) - pyrrolidin-2-one compounds as phosphodiesterase 4 inhibitors
US7034051B2 (en) * 2003-08-28 2006-04-25 Adolor Corporation Fused bicyclic carboxamide derivatives and methods of their use
EP1663968A1 (en) * 2003-09-05 2006-06-07 Ranbaxy Laboratories Limited Process for the preparation of pure levetiracetam
US7629474B2 (en) * 2003-09-24 2009-12-08 Ucb Pharma S.A. Process for preparing 2-oxo-1-pyrrolidine derivatives
BRPI0417157A (pt) * 2003-12-02 2007-03-06 Ucb Sa composto, composição farmacêutica, e, uso de um composto ou de uma composição farmacêutica
KR101159870B1 (ko) 2004-06-11 2012-06-25 유씨비 소시에떼아노님 분자내 알릴화에 의해 2-옥소-1-피롤리딘 유도체를제조하는 방법
EP1831154B1 (en) * 2004-06-21 2010-01-13 Warner-Lambert Company LLC Preparation of pregabalin and related compounds
US7427601B2 (en) * 2004-06-24 2008-09-23 Schwarz Pharma Ag Method for treating tremor
WO2006044955A1 (en) * 2004-10-20 2006-04-27 Memory Pharmaceuticals Corporation Phosphodiesterase 4 inhibitors
CA2488325C (en) * 2004-11-22 2010-08-24 Apotex Pharmachem Inc. Improved process for the preparation of (s)-alpha-ethyl-2-oxo-1-pyrrolidineacetamide and (r)-alpha-ethyl-2-oxo-1-pyrrolidineacetamide
CA2610695A1 (en) 2005-06-01 2006-12-07 Ucb Pharma, S.A. 2-oxo-1-pyrrolidine derivatives and their therapeutic use on the central nervous system
EP1731149A1 (en) * 2005-06-08 2006-12-13 Ucb S.A. Use of 2-oxo-1-pyrrolidone derivatives for the treatment of diseases characterized by progressive myoclonic epilepsy
MY143249A (en) * 2005-09-15 2011-04-15 Ucb Pharma Sa 4-substituted pyrrolidin-2-ones and their use
JP2007153755A (ja) * 2005-12-01 2007-06-21 Gifu Univ プロリン類縁体
WO2007065634A1 (en) * 2005-12-07 2007-06-14 Ucb Pharma, S.A. 3-carboxy- 2-oxo-1 -pyrrolidine derivatives and their uses
US8338621B2 (en) 2005-12-21 2012-12-25 Ucb S.A. Process for the preparation of 2-oxo-1-pyrrolidine derivatives
LV13630B (en) * 2006-03-16 2007-12-20 Olainfarm As Method of preparation and use of pharmaceutically active n-carbamoylmethyl-4(r)-phenyl-2-pyrrolidinone
BRPI0712325A2 (pt) * 2006-06-08 2012-01-10 Ucb Pharma Sa processo para a preparação de co-cristais de pirrolidinonas, co-cristal, composição farmacêutica, e, uso de um co-cristal
KR101518427B1 (ko) 2006-06-15 2015-05-08 유씨비 파르마 게엠베하 상승적 항경련 효과를 갖는 약제학적 조성물
WO2008021666A2 (en) * 2006-08-18 2008-02-21 Morton Grove Pharmaceuticals, Inc. Stable liquid levetiracetam compositions and methods
KR101181194B1 (ko) * 2006-10-18 2012-09-18 화이자 프로덕츠 인코포레이티드 바이아릴 에터 우레아 화합물
WO2008103319A2 (en) 2007-02-16 2008-08-28 Ark Diagnostics, Inc. Compounds and methods for use in detecting gabapentin
WO2008132139A2 (en) * 2007-04-27 2008-11-06 Ucb Pharma S.A. New heterocyclic derivatives useful for the treatment of cns disorders
US20090082422A1 (en) * 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched levetiracetam
CA2715685C (en) * 2008-03-03 2015-04-28 Eric Schenkel Pharmaceutical solutions, process of preparation and therapeutic uses
US7741327B2 (en) 2008-04-16 2010-06-22 Hoffmann-La Roche Inc. Pyrrolidinone glucokinase activators
US20110212944A1 (en) * 2008-07-01 2011-09-01 Julie Liu 2-oxo-1-pyrrolidine derivatives
EP2147911A1 (en) 2008-07-24 2010-01-27 ZaCh System S.p.A. Process for the preparation of levetiracetam
JP4644881B2 (ja) * 2008-09-19 2011-03-09 高砂香料工業株式会社 ルテニウム錯体の製造方法
CN102227217A (zh) 2008-10-16 2011-10-26 约翰斯.霍普金斯大学 改善认知功能的方法和组合物
US8168756B2 (en) 2008-10-24 2012-05-01 Ark Diagnostics, Inc. Levetiracetam immunoassays
EP2341777B1 (en) * 2008-11-07 2015-01-21 NovaBay Pharmaceuticals, Inc. Antimicrobial oxazolidinone, hydantoin and imidazolidinone compositions
ES2602606T3 (es) * 2008-11-18 2017-02-21 Ucb Biopharma Sprl Formulaciones de liberación prolongada que comprenden un derivado de 2-oxo-1-pirrolidina
KR101689688B1 (ko) * 2008-11-18 2016-12-26 유씨비 파마, 에스.에이. ２­옥소­１­피롤리딘 유도체를 포함하는 지연 방출형 제형
FR2939311A1 (fr) * 2008-12-08 2010-06-11 Oreal Utilisation d'un derive diester de pyrrolidinone 4-carboxy comme solvant dans les compositions cosmetiques ; compositions cosmetiques les contenant
US8563036B2 (en) 2009-02-09 2013-10-22 Ucb Pharma, S.A. Pharmaceutical compositions comprising Brivaracetam
US8846411B2 (en) * 2009-06-11 2014-09-30 Microgenics Corporation Derivatives, reagents, and immunoassay for detecting levetiracetam
US20120171125A1 (en) 2009-08-07 2012-07-05 Ucb Pharma, S.A. Methods for Enhancing the Cognitive Function
US7939676B2 (en) 2009-09-17 2011-05-10 Zach System S.P.A. Process for the preparation of levetiracetam
US8487591B1 (en) 2009-12-31 2013-07-16 Cirrus Logic, Inc. Power control system with power drop out immunity and uncompromised startup time
SI2491045T1 (sl) 2009-10-23 2016-04-29 Ucb Biopharma Sprl 2-okso-1-pirolidinil imidazotiadiazolni derivati
PL389364A1 (pl) 2009-10-23 2011-04-26 Uniwersytet Jagielloński Nowe zastosowanie pochodnych 2-pirolidonu
EP2533645B1 (en) 2010-02-09 2016-07-27 The Johns Hopkins University Methods and compositions for improving cognitive function
FR2961099B1 (fr) 2010-06-09 2012-06-15 Oreal Derives de 2-pyrrolidone fonctionnalisee par un radical ester, acide ou amide, la composition cosmetique les comprenant et leur utilisation pour le conditionnement des matieres keratiniques
FR2961098A1 (fr) 2010-06-09 2011-12-16 Oreal Composition comprenant au moins une 2-pyrrolidone fonctionnalisee en position 4 par un acide carboxylique ou amide, et au moins un colorant direct ou un pigment pour la teinture des fibres keratiniques
FR2961101B1 (fr) 2010-06-09 2013-01-25 Oreal Composition comprenant au moins une 2-pyrrolidone fonctionnalisee par un radical ester ou amide, et au moins un pigment ou un colorant direct pour la teinture des matieres keratiniques
US8866452B1 (en) 2010-08-11 2014-10-21 Cirrus Logic, Inc. Variable minimum input voltage based switching in an electronic power control system
US9510401B1 (en) 2010-08-24 2016-11-29 Cirrus Logic, Inc. Reduced standby power in an electronic power control system
US8466297B2 (en) 2010-11-01 2013-06-18 Milan Soukup Manufacturing process for (S)-Pregabalin
CA2818025A1 (en) 2010-11-15 2012-05-24 Agenebio, Inc. Pyridazine derivatives, compositions and methods for treating cognitive impairment
US20120214859A1 (en) * 2011-02-09 2012-08-23 Michela Gallagher Methods and compositions for improving cognitive function
ME02351B (me) 2011-04-18 2016-06-20 Ucb Biopharma Sprl Derivati 2 -oxo- 1-imidazolidinil imidazotiadiazol
CN103636109B (zh) 2011-06-03 2016-08-17 塞瑞斯逻辑公司 用于操作开关电力转换器的方法和装置以及电力分配系统
IN2014CN03043A (no) 2011-09-30 2015-07-03 Univ Tufts
WO2013100568A1 (en) * 2011-12-27 2013-07-04 Bio-Pharm Solutions Co., Ltd. Phenyl carbamate compounds for use in preventing or treating stroke
TW201408293A (zh) * 2012-07-05 2014-03-01 Merz Pharma Gmbh & Co Kgaa (r)-苯基披喇瑟盪於治療疾病相關疲勞之用途
TW201408294A (zh) * 2012-07-05 2014-03-01 Merz Pharma Gmbh & Co Kgaa (r)-苯基披喇瑟盪於治療帕金森氏症之用除
CA2885369A1 (en) 2012-09-28 2014-04-03 Tufts University Uridine diphosphate derivatives, prodrugs, compositions and uses thereof
EP2919788A4 (en) 2012-11-14 2016-05-25 Univ Johns Hopkins METHODS AND COMPOSITIONS FOR THE TREATMENT OF SCHIZOPHRENIA
DK2928865T3 (en) 2012-12-07 2018-06-18 Merck Sharp & Dohme BIOCATALYTIC TRANSAMINATION PROCEDURE
WO2014087367A2 (en) * 2012-12-09 2014-06-12 Mahesh Kandula Compositions and methods for the treatment of neurological diseases and its associated complications
EP2945942B1 (en) 2013-01-18 2018-05-09 ARK Diagnostics, Inc. Voriconazole immunoassays
ES2674704T3 (es) 2013-02-13 2018-07-03 Ark Diagnostics, Inc. Inmunoensayos de posaconazol
CA2904180C (en) 2013-03-13 2022-05-10 Tufts University Uridine nucleoside derivatives, compositions and methods of use
AR095442A1 (es) 2013-03-13 2015-10-14 Univ Tufts Derivados de nucleósido de uridina, composiciones y métodos de uso
EP2968237A4 (en) 2013-03-15 2016-08-31 Univ Johns Hopkins METHOD AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION
DK2968220T3 (da) 2013-03-15 2021-06-14 Agenebio Inc Fremgangsmåder og sammensætninger til forbedring af kognitiv funktion
CN103342672B (zh) * 2013-07-02 2015-12-23 扬州大学 取代吡咯烷-2-酮的新合成方法
JP6465634B2 (ja) * 2013-12-05 2019-02-06 株式会社日本触媒 環状アミド基含有重合体
JP6453632B2 (ja) * 2013-12-05 2019-01-16 株式会社日本触媒 環状アミドアクリレート含有組成物およびその製造方法
EP3083569B1 (en) 2013-12-20 2022-01-26 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
ME03518B (me) 2014-01-21 2020-04-20 Janssen Pharmaceutica Nv Kombinacije koje obuhvataju pozitivne alosterične modulatore ili ortosterične agoniste metabotropnog glutamatergičnog receptora podtipa 2 i njihova primjena
WO2015110435A1 (en) 2014-01-21 2015-07-30 Janssen Pharmaceutica Nv Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use
CN104098497B (zh) * 2014-06-17 2016-04-13 王庚禹 一种新的酰胺类化合物
WO2016075082A1 (en) 2014-11-10 2016-05-19 Sandoz Ag Stereoselective reductive amination of alpha-chiral aldehydes using omega-transaminases for the synthesis of precursors of pregabalin and brivaracetam
US20180021307A1 (en) 2015-02-20 2018-01-25 Ucb Biopharma Sprl Combination Treatment
WO2016191435A1 (en) * 2015-05-25 2016-12-01 Peng Wang Processes to produce brivaracetam
CN108689968B (zh) * 2015-05-25 2020-09-15 苏州鹏旭医药科技有限公司 两种化合物及其制备方法和在合成布瓦西坦中的用途
CN106365986B (zh) * 2015-07-21 2019-01-08 苏州鹏旭医药科技有限公司 化合物及其制备方法和在合成布瓦西坦中的用途
CN107922457B (zh) 2015-06-19 2022-05-13 森托瑞恩生物制药公司 用于控制药物释放的递送系统
WO2016205739A1 (en) 2015-06-19 2016-12-22 Belew Mekonnen Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
WO2017076737A1 (en) 2015-11-03 2017-05-11 Ucb Biopharma Sprl Continuous process for preparing brivaracetam
SI3371150T1 (sl) 2015-11-03 2021-11-30 UCB Biopharma SRL Postopek za pripravo brivaracetama
CN106748748B (zh) * 2015-11-10 2021-08-24 成都国为生物医药有限公司 一种布瓦西坦的制备方法及其中间体
EP3397253A1 (en) 2015-12-30 2018-11-07 Adamas Pharmaceuticals, Inc. Methods and compositions for the treatment of seizure-related disorders
CN105646319B (zh) * 2015-12-30 2018-05-18 佛山市隆信医药科技有限公司 一种布瓦西坦的制备方法
EP3452447A4 (en) 2016-05-03 2019-12-18 The Regents of The University of California IRES-MEDIATED PROTEIN SYNTHESIS INHIBITORS
RU2629117C1 (ru) * 2016-06-14 2017-08-24 Сизов Владимир Владимирович Способ получения 4-замещенного 2-[2-оксо-1-пирролидинил] ацетамида
CN107513031B (zh) * 2016-06-16 2022-08-02 上海医药集团股份有限公司 一种2-氧代-1-吡咯烷手性衍生物的制备方法
BR112019012821A2 (pt) 2016-12-19 2019-11-26 Agenebio Inc derivados de benzodiazepina, composições e métodos para o tratamento do comprometimento cognitivo
US20180170941A1 (en) 2016-12-19 2018-06-21 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
AU2018210393A1 (en) 2017-01-20 2019-07-25 The Regents Of The University Of California Inhibitors of the N-terminal domain of the androgen receptor
WO2018141276A1 (zh) * 2017-02-05 2018-08-09 苏州鹏旭医药科技有限公司 布瓦西坦中间体的晶型a及其制备方法和布瓦西坦的晶型c及其制备方法
CN106866483A (zh) * 2017-02-05 2017-06-20 苏州鹏旭医药科技有限公司 布瓦西坦的晶型c及其制备方法
CN108503610B (zh) 2017-02-24 2019-09-13 北京艾百诺医药股份有限公司 一种光学纯的(r)-4-正丙基-二氢呋喃-2(3h)-酮的制备方法
CN108658831B (zh) * 2017-03-30 2021-11-05 江苏豪森药业集团有限公司 2-氧代-1-吡咯烷衍生物或其盐的制备方法
EP3615513B1 (en) 2017-04-24 2022-07-20 Tesaro, Inc. Methods of manufacturing of niraparib
JP7221227B2 (ja) 2017-06-30 2023-02-13 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 発毛を調節するための組成物及び方法
CN107793342A (zh) * 2017-10-19 2018-03-13 丽珠集团新北江制药股份有限公司 一种布瓦西坦的制备方法
CN107721896A (zh) * 2017-10-19 2018-02-23 丽珠集团新北江制药股份有限公司 一种布瓦西坦的中间体的制备方法
MX2020005472A (es) 2017-11-30 2020-11-11 Centurion Biopharma Corp Sistemas de administración de fármacos a base de maitansinoide.
CN111712511B (zh) 2017-11-30 2024-07-16 拉德克斯公司 澳瑞他汀e衍生物的白蛋白结合产物
WO2019152536A1 (en) 2018-01-30 2019-08-08 The Regents Of The University Of California Inhibitors of the wnt/beta-catenin pathway
CN108147988B (zh) * 2018-02-13 2020-10-02 扬州奥锐特药业有限公司 一种高手性纯度内酰胺化合物的制备方法
CN108530402B (zh) * 2018-04-10 2020-06-26 浙江工业大学 一种(R)-3-丙基-γ-丁内酯的制备方法
EP3566760A1 (en) * 2018-05-07 2019-11-13 Universite Libre De Bruxelles Method for nucleating crystals from a solution in a capillary tube
ES2947618T3 (es) 2018-05-08 2023-08-14 UCB Biopharma SRL Derivados de 1-imidazotiadiazolo-2H-pirrol-5-ona
CN112601749B (zh) 2018-06-19 2024-03-26 艾吉因生物股份有限公司 用于治疗认知损害的苯并二氮杂环庚三烯衍生物，组合物和方法
CN110615744B (zh) * 2018-06-20 2023-01-06 上海朴颐化学科技有限公司 一种布瓦西坦中间体及其制备方法
WO2020006489A1 (en) 2018-06-29 2020-01-02 The Regents Of The University Of California New molecular tweezers against neurological disorders and viral infections
RU2699669C1 (ru) * 2018-07-04 2019-09-09 Общество С Ограниченной Ответственностью "Валента - Интеллект" Новые составы N-карбамоилметил-4-фенил-2-пирролидона
SG11202100429TA (en) 2018-07-27 2021-02-25 California Inst Of Techn Cdk inhibitors and uses thereof
US11214568B2 (en) 2018-10-18 2022-01-04 California Institute Of Technology Gem-disubstituted pyrrolidines, piperazines, and diazepanes, and compositions and methods of making the same
US20220047548A1 (en) 2018-12-04 2022-02-17 Metys Pharmaceuticals AG SYNERGISTIC COMPOSITIONS COMPRISING (R)-2-(2-OXOPYRROLIDIN-1-YL)BUTANAMIDE AND (S)-2-(2-e OXOPYRROLEDIN-1-YL)BUTANAMEDE IN A NON-RACEMIC RATIO
CN109932442A (zh) * 2019-03-04 2019-06-25 成都美域高制药有限公司 一种布瓦西坦异构体的检测方法
WO2020198323A1 (en) 2019-03-25 2020-10-01 California Institute Of Technology Prmt5 inhibitors and uses thereof
SG11202112827QA (en) 2019-06-04 2021-12-30 Hager Biosciences Llc Imidazolo derivatives, compositions and methods as orexin antagonists
CN110357752A (zh) * 2019-08-15 2019-10-22 中国工程物理研究院化工材料研究所 一种快速制备均匀包覆含能材料的方法
RU2732245C1 (ru) * 2019-08-30 2020-09-14 Ооо "Валента-Интеллект" Новые составы n-карбамоилметил-4-фенил-2-пирролидона для лечения и профилактики ожирения
CN110551050A (zh) * 2019-09-02 2019-12-10 南通大学 一种2-[3’-(N-Boc-吡咯基)]-苯甲酸的合成方法
US10781170B1 (en) 2019-10-21 2020-09-22 Divi's Laboratories Ltd. Process for preparing Brivaracetam
US20230100559A1 (en) 2020-01-07 2023-03-30 The Trustees Of Princeton University Compositions and Methods for Treatment of Disease by Manipulation of Serine Metabolism
EP4087847A4 (en) 2020-01-10 2024-02-28 The Regents of the University of California COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASES
US20230174460A1 (en) 2020-04-21 2023-06-08 President And Fellowes Of Harvard College Afmt analogs and their use in methods of treating parkinson's disease
LV15614A (lv) 2020-07-30 2022-02-20 Latvijas Organiskās Sintēzes Institūts 2-(2-okso-3-pirolin-1-il)acetamīdi kā pretkrampju līdzekļi
US20230265082A1 (en) 2020-08-10 2023-08-24 Dana-Farber Cancer Institute, Inc. Substituted 1,2,4-oxadiazoles as small molecule inhibitors of ubiquitin-specific protease 28
CA3191166A1 (en) 2020-08-10 2022-02-17 Dana-Farber Cancer Institute, Inc. Substituted 3-amino-4-methylbenzenesulfonamides as small molecule inhibitors of ubiquitin-specific protease 28
WO2022035806A1 (en) 2020-08-10 2022-02-17 Dana-Farber Cancer Institute, Inc. Fused tricyclic pyrimidine-thieno-pyridine small molecule inhibitors of ubiquitin-specific protease 28
CN116323571A (zh) 2020-10-23 2023-06-23 丹娜法伯癌症研究院 肌酸激酶（ck）的共价抑制剂以及其用于治疗和预防癌症的用途
WO2022133237A2 (en) 2020-12-18 2022-06-23 Cornell University Methods of treating neurodegenerative disorders and stat3-linked cancers using suppressors of electron leak
WO2022140289A1 (en) 2020-12-21 2022-06-30 Cornell University Peptide-linked drug delivery system
US20240132480A1 (en) 2021-01-08 2024-04-25 Cornell University Inhibitors of mycobacterium tuberculosis lipoamide dehydrogenase
US11400074B1 (en) 2021-02-01 2022-08-02 Divi's Laboratories Ltd. Enzymatic process for the preparation of (2S)-2-[(4R)-2-oxo-4-propyl-pyrrolidin-1-yl]butyric acid and its conversion into brivaracetam
US11384050B1 (en) 2021-02-03 2022-07-12 Vitaworks Ip, Llc Method for preparing levetiracetam and intermediates thereof
CN114948953A (zh) * 2021-06-29 2022-08-30 四川大学华西医院 一种杂原子取代芳香类化合物及其盐的用途
CN113511994B (zh) * 2021-08-16 2023-03-21 江苏八巨药业有限公司 一种左乙拉西坦的制备方法
CN114634437B (zh) * 2022-03-29 2023-05-30 武汉氟本氘合新材料科技有限公司 一种布瓦西坦的简易制备方法
US11884623B2 (en) 2022-05-23 2024-01-30 Divi's Laboratories Ltd. Process for the preparation of (R)-4-propyl pyrrolidine-2-one, a key intermediate for synthesis of brivaracetam
WO2023250157A1 (en) 2022-06-24 2023-12-28 Cornell University Inhibitors of mycobacterium tuberculosis lipoamide dehydrogenase
WO2024013209A1 (en) 2022-07-13 2024-01-18 Astrazeneca Ab Pcsk9 inhibitors and methods of use thereof
WO2024039886A1 (en) 2022-08-19 2024-02-22 Agenebio, Inc. Benzazepine derivatives, compositions, and methods for treating cognitive impairment
WO2024049236A1 (ko) * 2022-08-31 2024-03-07 고려대학교 산학협력단 키랄 감마 락탐 유도체 또는 이의 약학적으로 허용가능한 염 및 이의 제조방법
WO2024163711A1 (en) 2023-02-02 2024-08-08 Osmoses Inc. Norbornyl benzocyclobutene ladder polymer composite membranes for fluid separation
EP4431086A1 (en) 2023-03-16 2024-09-18 Adalvo Limited Pharmaceutical composition comprising (2s)-2-[(4r)-2-oxo-4-propyltetrahydro-1h-pyrrol-1-yl]butanamide

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE92031C (no)
DD92031A (no) *
US2836599A (en) * 1957-03-07 1958-05-27 Aerojet General Co Nu-(carboxyalkyl) dinitro lactams
GB1309692A (en) * 1970-02-13 1973-03-14 Ucb Sa N-substituted lactams
GB1039113A (en) 1964-08-06 1966-08-17 Ucb Sa New n-substituted lactams
US4008281A (en) 1973-12-03 1977-02-15 Monsanto Company Asymmetric catalysis
HU177239B (hu) 1974-10-15 1981-08-28 Monsanto Co Eljárás N-acetamido-L-alanin-származékok előállítására α-acetamido-akrilsav-származékok aszimmetrikus katalitikus hídrogénezésével
GB8412358D0 (en) 1984-05-15 1984-06-20 Ucb Sa Pharmaceutical composition
CN1015542B (zh) * 1984-05-15 1992-02-19 尤西比公司 (R)-α-乙基-2-氧代-1-吡咯烷乙酰胺的制备方法
GB8412357D0 (en) * 1984-05-15 1984-06-20 Ucb Sa Pharmaceutical composition
JPS60166692A (ja) 1984-09-28 1985-08-29 Kazuo Achinami 新規不斉還元試薬
CH666891A5 (de) * 1985-11-26 1988-08-31 Lonza Ag 4-alkoxy-2-oxo-pyrrolidin-1-yl-essigsaeure-c(1)-c(4)-alkylester, deren herstellung und verwendung.
DE3719873A1 (de) * 1987-06-13 1988-12-29 Basf Ag Verfahren zur herstellung von itaconsaeurediestern und itaconsaeure
JPH0757758B2 (ja) 1988-10-24 1995-06-21 高砂香料工業株式会社 ルテニウム―ホスフィン錯体
GB8827389D0 (en) 1988-11-23 1988-12-29 Ucb Sa Process for preparation of(s)alpha-ethyl-2-oxo-1-pyrrolidineacetamide
SK279285B6 (sk) * 1991-05-02 1998-09-09 Daiichi Pharmaceutical Co. Použitie n-(2,6-dimetylfenyl)-2-(2-oxo-1-pyrolidin
US5171892A (en) 1991-07-02 1992-12-15 E. I. Du Pont De Nemours And Company Chiral phospholanes via chiral 1,4-diol cyclic sulfates
GB9319732D0 (en) 1993-09-24 1993-11-10 Ucb Sa Use of (s)-alpha-ethyl-2-oxo-l-pyrrolidineacetamide for the treatment of anxiety
JPH1180027A (ja) * 1997-09-12 1999-03-23 Dai Ichi Seiyaku Co Ltd 向知性薬
TW544311B (en) * 1998-08-06 2003-08-01 Daiichi Seiyaku Co Therapeutic or preventive agent for intractable epilepsies
CZ20001055A3 (cs) * 1998-10-02 2000-08-16 Dupont Pharmaceuticals Company Nové laktamové inhibitory metaloproteázy
ATE361751T1 (de) 1999-12-01 2007-06-15 Ucb Sa Ein pyrrolidinacetatderivat zur behandlung von chronischem oder neuropathischem schmerz
GB0004297D0 (en) * 2000-02-23 2000-04-12 Ucb Sa 2-oxo-1 pyrrolidine derivatives process for preparing them and their uses
US6686477B2 (en) 2000-09-29 2004-02-03 Eastman Chemical Company Highly enantiomerically pure lactam-substituted propanoic acid derivatives and methods of making and using same

Also Published As

Publication number Publication date
RU2006125756A (ru) 2008-01-27
HUP0204526A2 (hu) 2003-04-28
FR16C1001I1 (fr) 2016-07-01
US20120035239A1 (en) 2012-02-09
JP2003523996A (ja) 2003-08-12
SI1265862T1 (sl) 2006-02-28
AU2001252144B2 (en) 2005-04-28
KR100681580B1 (ko) 2007-02-09
EP1263727A1 (en) 2002-12-11
MXPA02008206A (es) 2004-04-05
HK1052516A1 (en) 2003-09-19
HK1052695B (zh) 2005-05-06
RU2005125569A (ru) 2007-02-20
CN1404470A (zh) 2003-03-19
IS7921A (is) 2005-06-29
IL150757A0 (en) 2003-02-12
EP1477478B1 (en) 2010-11-17
NO2023025I1 (no) 2023-06-20
HU230270B1 (hu) 2015-11-30
ES2248307T3 (es) 2006-03-16
ATE304999T1 (de) 2005-10-15
DE60107216D1 (de) 2004-12-23
PL365159A1 (en) 2004-12-27
RU2002124865A (ru) 2004-01-10
RO121597B1 (ro) 2007-12-28
LU92993I2 (fr) 2016-05-11
BR0108657A (pt) 2003-04-29
IL166768A (en) 2010-04-15
ZA200205671B (en) 2003-11-10
WO2001064637A1 (en) 2001-09-07
DE60119397D1 (de) 2006-06-08
WO2001062726A3 (en) 2002-01-17
US7217826B2 (en) 2007-05-15
IS7919A (is) 2005-06-29
HUS1600017I1 (hu) 2020-02-28
IL170181A (en) 2010-11-30
NO20023995L (no) 2002-10-21
TW200626545A (en) 2006-08-01
US20040087646A1 (en) 2004-05-06
RU2291860C3 (ru) 2017-11-16
US20100222576A1 (en) 2010-09-02
BRPI0108664B1 (pt) 2016-07-26
AU2001252144C1 (en) 2008-03-20
BG107004A (bg) 2003-04-30
DE60113514T2 (de) 2006-05-18
YU63202A (sh) 2005-09-19
DE60113514D1 (de) 2005-10-27
EP1263727B1 (en) 2004-11-17
HUP0204526A3 (en) 2005-03-29
CN1179944C (zh) 2004-12-15
DE60143493D1 (de) 2010-12-30
US6784197B2 (en) 2004-08-31
EP1265862B1 (en) 2005-09-21
AU2005200717A1 (en) 2005-03-17
MEP6109A (en) 2011-12-20
PL213669B1 (pl) 2013-04-30
CO5280059A1 (es) 2003-05-30
ES2264060T3 (es) 2006-12-16
KR100759145B1 (ko) 2007-09-14
KR100720784B1 (ko) 2007-05-23
MY140593A (en) 2009-12-31
DE60119397T2 (de) 2007-04-19
NO20023997D0 (no) 2002-08-22
CY1109718T1 (el) 2014-08-13
NO2016005I2 (no) 2016-03-08
IS7918A (is) 2005-06-29
RU2292336C2 (ru) 2007-01-27
JP4938259B2 (ja) 2012-05-23
MY127149A (en) 2006-11-30
KR20020075926A (ko) 2002-10-07
EP1447399B9 (en) 2006-10-18
IL150842A0 (en) 2003-02-12
CN1680314A (zh) 2005-10-12
US8492416B2 (en) 2013-07-23
ATE325093T1 (de) 2006-06-15
EG24375A (en) 2009-03-19
NO2016005I1 (no) 2016-03-08
CY2016022I1 (el) 2016-10-05
EP1452524A1 (en) 2004-09-01
BG65923B1 (bg) 2010-05-31
HK1052695A1 (en) 2003-09-26
CY2016022I2 (el) 2016-10-05
IS7922A (is) 2005-06-29
AU2005200717B2 (en) 2007-05-17
US6713635B2 (en) 2004-03-30
CA2401048A1 (en) 2001-09-07
JP2006022107A (ja) 2006-01-26
JP4769756B2 (ja) 2011-09-07
BRPI0108664B8 (pt) 2021-05-25
BG65783B1 (bg) 2009-11-30
CA2401033A1 (en) 2001-08-30
KR20050090090A (ko) 2005-09-12
AU2005200718A1 (en) 2005-03-17
KR20050091112A (ko) 2005-09-14
NO324485B1 (no) 2007-10-29
NZ520448A (en) 2004-03-26
PT1447399E (pt) 2006-09-29
AU7389601A (en) 2001-09-12
CU23293B7 (es) 2008-06-30
US20080097109A1 (en) 2008-04-24
HU229514B1 (en) 2014-01-28
AU778510B2 (en) 2004-12-09
BG65803B1 (bg) 2009-12-31
ATE445597T1 (de) 2009-10-15
SA01220027B1 (ar) 2006-09-19
DK1452524T3 (da) 2010-03-01
JP2006022108A (ja) 2006-01-26
CZ20022850A3 (cs) 2003-02-12
US20030040631A1 (en) 2003-02-27
RS50455B (sr) 2010-03-02
MXPA02008056A (es) 2004-08-12
RU2005125645A (ru) 2007-02-20
US7358276B2 (en) 2008-04-15
JP4121744B2 (ja) 2008-07-23
EP1447399B1 (en) 2006-05-03
ES2334998T3 (es) 2010-03-18
ES2231501T3 (es) 2005-05-16
IL150842A (en) 2008-06-05
BR0108664A (pt) 2003-04-29
NO324051B1 (no) 2007-08-06
CZ304420B6 (cs) 2014-04-30
NO20053645L (no) 2002-10-22
ZA200205837B (en) 2003-11-04
KR100816185B1 (ko) 2008-03-21
IS2754B (is) 2011-09-15
IS2119B (is) 2006-06-15
HK1052516B (zh) 2006-02-10
PT1452524E (pt) 2010-01-18
PL359388A1 (en) 2004-08-23
PL212197B1 (pl) 2012-08-31
EP1477478A2 (en) 2004-11-17
SA01220078B1 (ar) 2006-10-29
KR20020075927A (ko) 2002-10-07
CZ20022849A3 (cs) 2003-02-12
IS6481A (is) 2002-07-23
US20050171187A1 (en) 2005-08-04
US20030120080A1 (en) 2003-06-26
RU2291860C2 (ru) 2007-01-20
RO121559B1 (ro) 2007-11-30
WO2001062726A2 (en) 2001-08-30
US7692028B2 (en) 2010-04-06
EP1577296A1 (en) 2005-09-21
ATE282592T1 (de) 2004-12-15
NO20023995D0 (no) 2002-08-22
CN1740150A (zh) 2006-03-01
CN1208319C (zh) 2005-06-29
ATE488500T1 (de) 2010-12-15
BE2016C012I2 (no) 2020-01-30
CZ304702B6 (cs) 2014-09-03
NO20053644L (no) 2002-10-22
CA2401048C (en) 2009-01-20
PL210121B1 (pl) 2011-12-30
JP2007182459A (ja) 2007-07-19
EP1265862A2 (en) 2002-12-18
IS2176B (is) 2006-12-15
CY1105517T1 (el) 2010-07-28
CU23201A3 (es) 2007-04-06
FR16C1001I2 (fr) 2017-02-03
DK1265862T3 (da) 2006-01-30
HUP0300196A2 (hu) 2003-06-28
CN1404469A (zh) 2003-03-19
CO5271667A1 (es) 2003-04-30
DK1447399T3 (da) 2006-08-28
ME00595B (me) 2011-12-20
IL166768A0 (en) 2006-01-15
US20040192757A1 (en) 2004-09-30
BG109297A (en) 2006-06-30
JP4081275B2 (ja) 2008-04-23
GB0004297D0 (en) 2000-04-12
MY139420A (en) 2009-09-30
IS7923A (is) 2005-06-29
EP1477478A3 (en) 2004-11-24
US20040092576A1 (en) 2004-05-13
CA2401033C (en) 2008-07-29
IS7920A (is) 2005-06-29
HUP0300196A3 (en) 2005-10-28
ES2355140T3 (es) 2011-03-23
TW200626544A (en) 2006-08-01
DE60107216T2 (de) 2005-11-03
EP1447399A1 (en) 2004-08-18
RU2355680C2 (ru) 2009-05-20
US6806287B2 (en) 2004-10-19
HU0500902D0 (en) 2005-12-28
EP1577295A1 (en) 2005-09-21
LTPA2016013I1 (lt) 2016-05-25
US20050171188A1 (en) 2005-08-04
RS50454B (sr) 2010-03-02
AU5214401A (en) 2001-09-03
US6911461B2 (en) 2005-06-28
CN1740151A (zh) 2006-03-01
CN1303066C (zh) 2007-03-07
EP1452524B1 (en) 2009-10-14
DE60140222D1 (de) 2009-11-26
JP2003528828A (ja) 2003-09-30
US6969770B2 (en) 2005-11-29
EP1604979A1 (en) 2005-12-14
LTC1265862I2 (lt) 2023-09-11
AU2005200718B2 (en) 2007-05-24
MY138966A (en) 2009-08-28
US20040116507A1 (en) 2004-06-17
US20050159475A1 (en) 2005-07-21
BG107016A (en) 2003-04-30
IS6472A (is) 2002-07-16
YU63102A (sh) 2005-09-19
NL300815I2 (no) 2016-07-27
US6858740B2 (en) 2005-02-22
US8034958B2 (en) 2011-10-11

Similar Documents

Publication Publication Date Title
NO20023997L (no) 2-okso-1-pyrrolidinderivater, fremgangsmåter for deres fremstilling, og deres anvendelse

Legal Events

Date Code Title Description
SPCF Filing of supplementary protection certificate

Free format text: PRODUCT NAME: BRIVIACT; REG. NO/DATE: EU/1/15/1073 20160121

Spc suppl protection certif: 2016005

Filing date: 20160308

CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: UCB BIOPHARMA SPRL, BE

SPCG Granted supplementary protection certificate

Free format text: PRODUCT NAME: BRIVARACETAM; REG. NO/DATE: EU/1/15/1073 20160121

Spc suppl protection certif: 2016005

Filing date: 20160308

Extension date: 20260221

MK1K Patent expired
SPCF Filing of supplementary protection certificate

Free format text: PRODUCT NAME: BRIVARACETAM - FORLENGELSE; REG. NO/DATE: EU/1/15/1073 20160121

Spc suppl protection certif: 2023025

Filing date: 20230620